6:33 PM
 | 
Oct 15, 2012
 |  BC Extra  |  Company News

Aegerion gains on lomitapide briefing documents

Shares of Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained on Monday after FDA reviewers said lomitapide was "effective" at reducing LDL-C, total cholesterol, apolipoprotein B and triglycerides in patients with homozygous familial hypercholesterolemia (hoFH) in the product's only Phase III trial. The reviewers also said the company's proposed REMS would "support appropriate use of lomitapide, allowing it to be approved" for hoFH, while...

Read the full 293 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >